Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1027664
Keywords
ctDNA; liquid biopsy; NSCLC; therapy monitoring; minimal residual disease (MRD)
Categories
Funding
- National Natural Science Foundation of China
- Jiangsu National Natural Science Foundation
- [81902327]
- [82172708]
- [BK20191064]
Ask authors/readers for more resources
ctDNA is a valuable detection tool for evaluating tumor burden, specific cancer mutations, and minimal residual disease. Recent clinical trials have shown the rationality and feasibility of using ctDNA to identify mutations and guide treatments in non-small cell lung cancer (NSCLC).
Circulating tumor DNA (ctDNA) has contributed immensely to the management of hematologic malignancy and is now considered a valuable detection tool for solid tumors. ctDNA can reflect the real-time tumor burden and be utilized for analyzing specific cancer mutations via liquid biopsy which is a non-invasive procedure that can be used with a relatively high frequency. Thus, many clinicians use ctDNA to assess minimal residual disease (MRD) and it serves as a prognostic and predictive biomarker for cancer therapy, especially for non-small cell lung cancer (NSCLC). Advanced methods have been developed to detect ctDNA, and recent clinical trials have shown the rationality and feasibility of ctDNA for identifying mutations and guiding treatments in NSCLC. Here, we have reviewed recently developed ctDNA detection methods and the importance of sequence analyses of ctDNA in NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available